| Impact of a five-dimensional framework on R&D productivity at AstraZeneca P Morgan, DG Brown, S Lennard, MJ Anderton, JC Barrett, U Eriksson, ... Nature reviews Drug discovery 17 (3), 167-181, 2018 | 438 | 2018 |
| The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects D Gustafsson, JE Nyström, S Carlsson, U Bredberg, U Eriksson, ... Thrombosis research 101 (3), 171-181, 2001 | 431 | 2001 |
| Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial BI Eriksson, P Kälebo, D Bergqvisty, OE Dahl, S Lindbratt, A Bylock, ... The Lancet 360 (9344), 1441-1447, 2002 | 306 | 2002 |
| Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes D Gustafsson, T Antonsson, R Bylund, U Eriksson, E Gyzander, I Nilsson, ... Thrombosis and haemostasis 59 (01), 110-118, 1998 | 254 | 1998 |
| Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. A Miniscalco, J Lundahl, CG Regårdh, B Edgar, UG Eriksson The Journal of pharmacology and experimental therapeutics 261 (3), 1195-1199, 1992 | 240 | 1992 |
| Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects UG Eriksson, U Bredberg, K Gislén, LC Johansson, L Frison, M Ahnoff, ... European journal of clinical pharmacology 59, 35-43, 2003 | 198 | 2003 |
| Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans UG Eriksson, U Bredberg, KJ Hoffmann, A Thuresson, M Gabrielsson, ... Drug metabolism and disposition 31 (3), 294-305, 2003 | 198 | 2003 |
| A new oral anticoagulant: the 50-year challenge D Gustafsson, R Bylund, T Antonsson, I Nilsson, JE Nyström, U Eriksson, ... Nature reviews Drug discovery 3 (8), 649-659, 2004 | 176 | 2004 |
| A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism … BI Eriksson, AC Arfwidsson, L Frison, UG Eriksson, A Bylock, P Kälebo, ... Thrombosis and haemostasis 87 (02), 231-237, 2002 | 174 | 2002 |
| Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber MU Zafar, DA Vorchheimer, J Gaztanaga, M Velez, D Yadegar, ... Thrombosis and Haemostasis 98 (10), 883-888, 2007 | 160 | 2007 |
| Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor LC Johansson, L Frison, U Logren, G Fager, D Gustafsson, UG Eriksson Clinical pharmacokinetics 42, 381-392, 2003 | 137 | 2003 |
| Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety … GYH Lip, LH Rasmussen, SB Olsson, EC Jensen, AL Persson, U Eriksson, ... European heart journal 30 (23), 2897-2907, 2009 | 123 | 2009 |
| Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions E Bredberg, TB Andersson, L Frison, A Thuresson, S Johansson, ... Clinical pharmacokinetics 42, 765-777, 2003 | 122 | 2003 |
| Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT H Eriksson, UG Eriksson, L Frison, PO Hansson, P Held, M Holmström, ... Thrombosis and haemostasis 81 (03), 358-363, 1999 | 119 | 1999 |
| Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers M Wolzt, M Levi, TC Sarich, SL Boström, UG Eriksson, ... Thrombosis and haemostasis 91 (06), 1090-1096, 2004 | 110 | 2004 |
| Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects TC Sarich, M Wolzt, UG Eriksson, C Mattsson, A Schmidt, S Elg, ... Journal of the American College of Cardiology 41 (4), 557-564, 2003 | 100 | 2003 |
| Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein … K Wåhlander, L Lapidus, CG Olsson, A Thuresson, UG Eriksson, ... Thrombosis research 107 (3-4), 93-99, 2002 | 96 | 2002 |
| The UK prospective diabetes study RC Turner, RR Holman Annals of medicine 28 (5), 439-444, 1996 | 86 | 1996 |
| Pharmacokinetics and metabolic fate of two nitroxides potentially useful as contrast agents for magnetic resonance imaging WR Couet, UG Eriksson, TN Tozer, LD Tuck, GE Wesbey, D Nitecki, ... Pharmaceutical research 1, 203-209, 1984 | 78 | 1984 |
| Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran UG Eriksson, S Johansson, PO Attman, H Mulec, L Frison, G Vager, ... Clinical pharmacokinetics 42, 743-753, 2003 | 76 | 2003 |
